Scientists have engineered a revolutionary chewing gum that dramatically reduces levels of microbes associated with head and neck cancer, showing up to a 93% decrease in one virus and two bacterial strains in early tests. Developed by researchers at the University of Pennsylvania's School of Dental Medicine, this innovative gum holds promise for more accessible and affordable cancer therapies.
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer where late-stage diagnoses often lead to poor outcomes. Lead researcher Henry Daniell notes that many current cancer treatments haven't significantly improved patient quality of life or long-term survival, underscoring the urgent need for novel approaches.
The new study builds on previous work with a chewing gum containing FRIL, an antiviral protein derived from lablab beans. This time, the team focused on three key microbes linked to HNSCC: human papillomavirus (HPV), and the bacteria Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn). "The global rise in oropharyngeal cancer is tied to HPV infection," explained Daniell. "And Pg and Fn infections worsen survival rates for untreated oral cancer, even after surgery and other therapies."
Results were striking: extracts from the bean gum slashed HPV levels by 93% in saliva samples and 80% in oral rinse samples. Further modifications to the gum incorporated protegrin, an antimicrobial peptide, which reduced Pg and Fn to near-zero levels after a single dose. Crucially, this treatment preserved beneficial oral bacteria, unlike radiation therapy which can harm good bacteria while promoting harmful yeast growth.
This dual action of targeting dangerous microbes while safeguarding the mouth's healthy microbiome opens up several therapeutic possibilities. Researchers envision the gum potentially serving as an adjunctive therapy alongside current cancer treatments or even as a preventive measure against infection and transmission. "Lip and oral cavity cancer was a major global concern in 2022, especially among young and middle-aged adults," Daniell stated. "Our findings strongly support advancing these therapies to clinical trials as support for current treatments or as a way to prevent infection and transmission."
